Overview Physical properties Uses Preparation Pharmacological effects Pharmacokinetics Clinical application Side effects
ChemicalBook > CAS DataBase List > Pirfenidone

Pirfenidone

Overview Physical properties Uses Preparation Pharmacological effects Pharmacokinetics Clinical application Side effects
Product Name
Pirfenidone
CAS No.
53179-13-8
Chemical Name
Pirfenidone
Synonyms
5-methyl-1-phenylpyridin-2(1H)-one;5-Methyl-1-phenylpyridine-2(1H)-one;Pirespa;Pirfenidone CRS;5-METHYL-1-PHENYL-2-(1H)-PYRIDONE;S-7701;amr-69;PIRFENIDONE;PIRFINIDONE;S-7701,AMR-69
CBNumber
CB5299210
Molecular Formula
C12H11NO
Formula Weight
185.22
MOL File
53179-13-8.mol
More
Less

Pirfenidone Property

Melting point:
96-97°C
Boiling point:
329.1±15.0 °C(Predicted)
Density 
1.137±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Room Temperature
solubility 
DMSO: ≥10 mg/mL, soluble
form 
solid
pka
-0.16±0.63(Predicted)
color 
Off-white
Water Solubility 
Soluble to 20 mM in water
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChI
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
InChIKey
ISWRGOKTTBVCFA-UHFFFAOYSA-N
SMILES
C1(=O)N(C2=CC=CC=C2)C=C(C)C=C1
CAS DataBase Reference
53179-13-8(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn
Risk Statements 
22
Safety Statements 
36-24/25
WGK Germany 
3
RTECS 
UV1148200
HS Code 
29337900
Hazardous Substances Data
53179-13-8(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
P2116
Product name
Pirfenidone
Purity
≥97% (HPLC)
Packaging
10mg
Price
$132
Updated
2024/03/01
Sigma-Aldrich
Product number
P2116
Product name
Pirfenidone
Purity
≥97% (HPLC)
Packaging
50mg
Price
$236.8
Updated
2024/03/01
TCI Chemical
Product number
P1871
Product name
Pirfenidone
Purity
>98.0%(GC)
Packaging
1g
Price
$330
Updated
2024/03/01
TCI Chemical
Product number
P1871
Product name
Pirfenidone
Purity
>98.0%(GC)
Packaging
100mg
Price
$58
Updated
2024/03/01
Cayman Chemical
Product number
13986
Product name
Pirfenidone
Purity
≥95%
Packaging
5mg
Price
$44
Updated
2024/03/01
More
Less

Pirfenidone Chemical Properties,Usage,Production

Overview

Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Physical properties

Pirfenidone is a white to pale yellow, non-hygroscopic powder. It is more soluble in methanol, ethyl alcohol, acetone and chloroform than in water and 1.0 N HCl. The melting point is approximately 109°C.

Uses

Pirfenidone is a broad-spectrum antifibrotic drug that modulates diverse cytokine action involving TGF-β, TNF-α, epidermal growth factor, platelet-derived growth factor,vascular endothelial growth factor, insulin-like growth factor 1, fibroblast growth factor, and others.Pirfenidone has been effective in the prevention and regression of pulmonary fibrosis, peritoneal sclerosis, hepatic cirrhosis, uterine fibromyoma, and other scarring and fibrotic conditions. It doesn’t cure the condition or reverse any existing scarring but it can effectively slow down the rate of lung function decline by about 50%. In the UK, Pirfenidone is currently only approved for treating IPF, and not for other forms of pulmonary fibrosis.

Preparation

(1) The synthesis of the 5-methyl-2 (1H)-pyridone③
Add 1500 g (13.87 mol) of 2-amino-5-methylpyridine②, 35 L of 5% sulfuric acid to the reaction kettle and stir at room temperature for 15 min. Cool to 0~5 °C after all the solid being totally dissolved. Slowly add 1665 g of sodium nitrite (24.1 mol) into 5 L of water, stir for maintaining temperature at 3h; after the completion of the reaction, heat and reflux until no more gas is generated; use sodium carbonate to adjust pH to neutral, evaporate to dryness under reduced pressure; add 25 L of methanol to the kettle, add 30 g of activated charcoal for heating and reflux for 20min, filter, evaporate the filtrate evaporated to dryness under reduced pressure with the residue being recrystallized by ethanol to obtain pale yellow crystals③.
(2)The Synthesis of pirfenidone ①
Successively add 1000 g (9.16 mol) of 5-methyl-2 (1H)-pyridone, 2245 g (11.01 mol) of iodobenzene, 1391 g (10.08 mol) of potassium carbonate, 32.1 g (0.32 mol) of cuprous chloride and 3.5 L of dimethylsulfoxide into the 10L 3-neck flask, and stir slowly to raise the temperature to 180 °C and maintain the reaction for about 5 h. After the completion of the reaction, cool to room temperature, filter the reaction solution, wash the filter cake with 1 L of dimethyl sulfoxide; combine the filtrate and evaporate to dryness under reduced pressure; add 3 L of 20% acetic acid aqueous solution, and heat to 65 °C; stir for 30 min; stand static for layer separation; further extract the lower oil with 20% aqueous acetic acid (1L X 3) and then combine the aqueous phases. Add solid sodium hydroxide to the aqueous phase to adjust the pH to 13, cool to room temperature, separate out the precipitate; filter; wash the filter cake with water; after drying the filter cake, add 3.2L of ethyl acetate for heating reflux for about 15 min; filter it in hot condition, cool for separate the crystals; allow it to stand overnight; filter; have the filter cake dried under reduced pressure for 5h to obtain the pirfenidone①.

Figure 1 The synthetic route of Pirfenidone (PFD)
This method is a modification of the method 1, which applies the diazotization of 2-amino--5-methylpyridine, hydrolyze to obtain 5-methyl-2 (1H)-pyridone, which have reaction together with bromobenzene in 1: 1.2 (molar ratio); Using DMF as the solvent, CuBr as the catalyst, add 5% of the 1,10-phenanthrolin as the ligand, have reaction at 90°C for 2 hours to obtain the pirfenidone.

Figure 2: The Synthetic route of pirfenidone

Pharmacological effects

PFD is a potent inhibitor of a cytokine by regulating or inhibiting certain factors, thus inhibiting the biological activities of fibroblast cells and reducing the cell proliferation and the synthesis of collagen matrix. Meanwhile, PFD can also inhibit the secretion of inflammatory mediators, reduce lipid peroxidation, and exert its anti-inflammatory and antioxidant effects.
1. Inhibition of collagen synthesis
Fibroblast growth factor (bFGF), transforming growth factor-β (transforming growth factor-β, TGF-β), connective tissue growth factor (connective tissue growth factor, CTGF) and tissue inhibitor of metalloproteinase 1 (TIMP-1) are growth factors that related with fibrotic diseases. They can promote fibroblast proliferation and growth, increase the synthesis of collagen matrix and prevent the degradation of extracellular matrix (ECM). They are expressed to different extent during the formation of organ fibrosis. PFD can effectively reduce the expression of the proteins such as bFGF, TGF-β, CTGF and TIMP-1 in the fibroblast cells of lung and kidney and be correlated with the reduction of collagen synthesis and matrix.
The formation of I and III type collagen fibers is also closely related to the synthesis of collagen matrix. At the same time of reducing TGF-β expression, PFD can also reduce the generation α I collagen. PFD also inhibit the expression of pulmonary fibrosis I collagen. In addition, PFD also has inhibitory effect on the expression of type III collagen mRNA and can reduce the synthesis of collagen type III.
2. The anti-inflammatory effects
PFD can inhibit to the inflammatory mediators to varying degrees for exerting their anti-inflammatory effects. When the inflammatory cytokines is overexpressed inside the lung, the inflammation reaction is exacerbated, thus making alveolar wall being thickening, reducing the function of pulmonary alveoli, and ultimately causing fibrosis. PFD primarily take anti-inflammatory effects by inhibiting the expression of inflammatory mediators, reducing vascular permeability, and reducing the agglomeration of neutropenia and inflammatory cells, thus further preventing or slowing down the fibrosis of organs and tissues.
3. Anti-oxidation effect
PFD mainly exert their antioxidant effects by scavenging free radicals and inhibiting lipid peroxidation and oxidative stress mitigation.

Pharmacokinetics

After the rat intravenous injection 400 mg• kg-1 of this product, the product is cleared from the plasma according to two-compartment model with a plasma clearance rate being 0.10mL • min-1 • g-1 and the apparent volume of distribution being 0.6 mL • g-1, and the half-life being 8.6min. After intravenous injection, pirfenidone is rapidly distributed in the body fluids with the drug concentration in the tissues reaching peak within 5 min with the concentration among liver, kidneys, lungs and other parts rich in blood containing relative high levels; the concentration in lower fat tissue is relative low; rat: oral administration of pirfenidone: 250~300 mg • kg-1 • d-1 yields a bioavailability of being 25.7%. The 24 h average plasma concentration is (1.9 ± 0.1) μg • mL-1after 14 day of drug administration; 97 % of the metabolites are excreted from the kidney with 24 h excretion accounting for 97% of the total.

Clinical application

1. Idiopathic pulmonary fibrosis degeneration
Idiopathic pulmonary fibrosis (IPF) is an unexplained, poor prognosis and high-mortality chronic inflammatory interstitial lung disease. At the same time, PFD is an anti-inflammatory, anti-fibrotic agent which can be used for the treatment of IPF.
2. Liver Fibrosis
3. Renal fibrosis disease
4. Multiple Sclerosis
Multiple sclerosis (MS) is a central nervous system-related and the immune-related inflammation and demyelinating diseases. Immune factors relating to it are activation of stellate cells, glial cell, and endothelial cell and the increase of lymphocytes, while PDF have effects of inhibiting the cell activation.
5. Myocardial fibrosis
Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can all lead to myocardial fibrosis, thereby resulting in the disease progression or development. Using PDF for treatment of cardiomyopathy caused by Duchenne muscular dystrophy can inhibit myocardial fibrosis, improve the cardiac function. PFD can reduce the incidence of atrial fibrillation and myocardial remodeling through inhibiting fibrosis.
6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas.
7. Prevention of fibrosis after the organ transplant.
8. Rheumatoid arthritis.

Side effects

Common adverse reactions include light sensitivity, fatigue, rash, and nausea; other adverse reactions also include upper gastrointestinal discomfort, bloating, anorexia, diarrhea, and skin itching.

Description

Until recently, IPF therapy consisted of a combination of corticosteroids and immunosuppressive agents (azathioprine and cyclophosphamide) to target the inflammation that was believed to be the pathogenic stimulus.Since IPF is now considered to be predominantly a disorder of fibroproliferation, agents that intervene in fibrogenesis have moved to the forefront of treatment options. With demonstrated efficacy in a bleomycin-induced lung fibrosis animal model, pirfenidone has been developed and launched as an approved therapy for IPF. Its antifibrotic activity is derived from the inhibition of p38 MAP kinase that is upstream of transforming growth factor-β (TGF-β), a cytokine implicated in the stimulation of collagen synthesis and the inhibition of its degradation. Pirfenidone also inhibits the expression of TNF-α, IL-1, and ICAM-1, so it possesses the dual benefit of an anti-inflammatory and antifibrotic agent. This relatively simplistic drug is constructed by the copper-catalyzed reaction of 5-methyl-2(1H)-pyridinone with bromo- or chlorobenzene. .

Chemical Properties

Off-White Solid

Originator

Marnac (United States)

Uses

Pirfenidone has been used:

  • as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery
  • as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit
  • to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)
  • as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia

Uses

Pirfenidone is in a group of medicines called antifibrotic agents. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It affects your body’s immune system and reduces the amount of fibrosis (scarring) in the lungs. Pirfenidone is one of two medicines that are approved in Canada to treat Idiopathic Pulmonary Fibrosis (IPF). Another name for this medicine is Esbriet.

Definition

ChEBI: A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.

brand name

Pirespa

General Description

Pirfenidone?(5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.

Biological Activity

Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo . Potent scavenger of free radicals and inhibitor of lipid peroxidation.

Biochem/physiol Actions

Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.

Synthesis

Pirfenidone may inhibit collagen synthesis, down-regulate production of multiple cytokines, and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone was prepared via a two step sequence as detailed in the scheme.2-Amino-5-methylpyridine (91) was converted to pyridone 92 by reaction with sulfuric acid and sodium nitrate at low temperature in 73% yield. Condensation of 5-methyl-2- (1H)-pyridone (92) with iodobenzene (93) in the presence of K2CO3 and CuCl at reflux gave pirfenidone (XIII) in 85% yield.

in vitro

in raw264.7 cells, pirfenidone (< 300 μg/ml) suppressed the proinflammatory cytokine tumor necrosis factor-α (tnf-α) through a translational mechanism, which was independent of activation of the mitogen-activated protein kinase (mapk)2, p38 map kinase, and c-jun n-terminal kinase (jnk)[1]. in ln-18, t98g, lnt-229 and ln-308 cell lines, pirfenidone (< 10 mm) reduced glioma cell density in a concentration-dependent manner. in ccl-64 cells, pirfenidone (< 5 mm) reduced tgf-β bioactivity by affecting tgf-β2 mrna expression and processing of pro-tgf-β. pirfenidone (< 8.3 mm) inhibited the activity of recombinant furin and downregulated the expression of mmp-11 in a dose-dependent manner in ln-308 cells[2].in cultured myometrial and leiomyoma smooth muscle cells, pirfenidone inhibited serum-stimulated increases in dna synthesis and cell proliferation in a dose-dependent manner[3].

in vivo

in animals, pirfenidone treatment significantly decreased gene expression of collagens i, iii and iv, transforming growth factor β-1, smad-7, timp-1 and pai-1 [4]. pirfenidone at a dose of 30 mg/kg/day t.i.d. attenuated the bleomycin-induced pulmonary fibrosi. pirfenidone (30, 100 mg/kg/day t.i.d) suppressed lung inflammatory edema and pulmonary fibrosis. pirfenidone suppressed the bleomycin-induced increase in lung interleukin (il)-1β, il-6, il-12\p40 and monocyte chemoattractant protein (mcp)-1 levels and prevented the bleomycin-induced decrease in lung interferon (ifn)-γ levels. furthermore, pirfenidone suppressed elevation of lung basic-fibroblast growth factor (bfgf), transforming growth factor (tgf)-β1 levels, lung stroma cell derived factor (sdf)-1α and il-18[5].

storage

Store at RT

References

1) Kehrer and Margolin (1997),?Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice; Toxicol.Lett.,?90?125 2) Iyet?et al.?(1999),?Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis; J.Pharmacol.Exp.Ther.,?289?211 3) Xie?et al.?(2002),?Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis; Respir.Res.,?17?103 4) Li?et al.?(2016),?Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-b signaling in a murine colitis model;?Biochem.Pharmacol.,?117?57 5) Nakazato?et al.?(2002),?A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level, Eur.J.Pharmacol.?446?177 6) Misra and Rabideau (2000),?Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals, Mol.Cell Biochem.?204?119 7) Canestaro?et al.?(2016),?Drug Treatment of Idiopathic Pulmonary Fibrosis: Systemic Review and Network Meta-Analysis; Chest,?149?756

Pirfenidone Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Pirfenidone Suppliers

Pure Chemistry Scientific Inc.
Tel
001-857-928-2050 or 1-888-588-9418
Fax
001-617-206-9595
Email
sales@chemreagents.com
Country
United States
ProdList
10186
Advantage
62
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Accela ChemBio Inc.
Tel
+1-858-6993322
Fax
(+1)-858-876-1948
Email
info@accelachem.com
Country
United States
ProdList
18478
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
United States Biological
Tel
--
Fax
--
Email
sales@advtechind.com
Country
United States
ProdList
6075
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6962
Advantage
56
Focus Biomolecules
Tel
--
Fax
--
Email
sales@focusbiomolecules.com
Country
United States
ProdList
1284
Advantage
58
Abcam
Tel
--
Fax
--
Email
us.orders@abcam.com
Country
United States
ProdList
6001
Advantage
50
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
MilliporeSigma (Sigma-Aldrich Corp.)
Tel
--
Fax
--
Email
@sial.com
Country
United States
ProdList
5414
Advantage
58
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
Fluorochem Ltd.
Tel
--
Fax
--
Email
enquiries@fluorochem.co.uk
Country
United States
ProdList
4583
Advantage
58
AstaTech, Inc.
Tel
--
Fax
--
Email
sales@astatechinc.com
Country
United States
ProdList
904
Advantage
58
Combi-Blocks, Inc.
Tel
--
Fax
--
Email
les@combi-blocks.com
Country
United States
ProdList
2555
Advantage
58
Jubilant Pharma Holdings Inc.
Tel
--
Fax
--
Email
bd.api@jubl.com
Country
United States
ProdList
39
Advantage
58
Interchem Corporation USA
Tel
--
Fax
--
Email
esa@interchem.com
Country
United States
ProdList
469
Advantage
58
TCI America, Inc. (part of Tokyo Chemical Industry)
Tel
--
Fax
--
Email
Angelina.Crew@tcichemicals.com
Country
United States
ProdList
2053
Advantage
58
SHAMROCK INDUSTRIAL CO. LTD.
Tel
--
Fax
--
Email
pharma@shamrockindia.com
Country
United States
ProdList
119
Advantage
43
Genegobio Inc.
Tel
--
Fax
--
Email
mark@genegobio.com
Country
United States
ProdList
195
Advantage
0
ACIC Fine Chemicals Inc.
Tel
--
Fax
--
Email
sales@acic.com
Country
United States
ProdList
492
Advantage
48
Oakwood Products, Inc.
Tel
--
Fax
--
Email
sales@oakwoodchemical.com
Country
United States
ProdList
6193
Advantage
74
RIA International LLC
Tel
--
Fax
--
Email
marketing@riausa.net
Country
United States
ProdList
1324
Advantage
50
Spectrum Chemicals & Laboratory Products
Tel
--
Fax
--
Email
sales@spectrumchemical.com
Country
United States
ProdList
6699
Advantage
77
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
MICRO LABS LTD
Tel
--
Fax
--
Email
calibration@microlabs-inc.com
Country
United States
ProdList
36
Advantage
58
MYLAN LABORATORIES LTD
Tel
--
Fax
--
Email
info@amstock.com
Country
United States
ProdList
179
Advantage
58
Combi-Blocks Inc.
Tel
--
Fax
--
Email
sales@combi-blocks.com
Country
United States
ProdList
6618
Advantage
69
SynChem,Inc
Tel
--
Fax
--
Email
sales@synchem.com
Country
United States
ProdList
4697
Advantage
58
Riedel-de Haen AG
Tel
--
Fax
--
Country
United States
ProdList
6773
Advantage
87
TCI America
Tel
--
Fax
--
Email
sales@tciamerica.com
Country
United States
ProdList
6909
Advantage
75
Frontier Scientific, Inc.
Tel
--
Fax
--
Email
sales@frontiersci.com
Country
United States
ProdList
6222
Advantage
86
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
Wilshire Chemical Company Inc.
Tel
--
Fax
--
Email
WilshrChem@AOL.COM
Country
United States
ProdList
3498
Advantage
58
Medical Isotopes
Tel
--
Fax
--
Email
stohler@medicalisotopes.com
Country
United States
ProdList
6181
Advantage
68
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
2A PharmaChem USA
Tel
--
Fax
--
Email
sales@2apharmachem.com
Country
United States
ProdList
6137
Advantage
39
More
Less

View Lastest Price from Pirfenidone manufacturers

Hebei Zhuanglai Chemical Trading Co.,Ltd
Product
Pirfenidone 53179-13-8
Price
US $10.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
20ton
Release date
2024-06-06
Hebei Mujin Biotechnology Co.,Ltd
Product
Pirfenidone 53179-13-8
Price
US $0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
20ton
Release date
2023-07-26
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
Product
Pirfenidone 53179-13-8
Price
US $100.00-75.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
5000
Release date
2024-08-14

53179-13-8, PirfenidoneRelated Search:


  • 5-Methyl-1-phenylpyridine-2(1H)-one
  • S-7701
  • 5-methyl-1-phenyl-2-pyridone
  • 5-methyl-1-phenyl-pyridin-2-one
  • 5-methyl-1-phenylpyridin-2-one
  • Pirfenidone, >=99%
  • 5-methyl-1-phenylpyridin-2(1H)-one
  • Pirfenidone(S-7701,AMR-69)
  • 2(1H)-Pyridinone,5-Methyl-1-phenyl-
  • Pirfenidone ( 5-Methyl-1-Phenyl-2(1H)-Pyridinone)
  • Pirfenidone SynonyMs 5-Methyl-1-phenyl-2-(1H)-pyridone
  • S-7701,AMR-69
  • Pirespa
  • 5-methyl-1-phenyl-2(1h)-pyridon
  • amr-69
  • PIRFENIDONE
  • 5-METHYL-1-PHENYL-1H-PYRIDIN-2-ONE
  • 5-METHYL-1-PHENYL-2(1H)-PYRIDINONE
  • 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE
  • 5-Methyl-N-phenyl-2-1H-pyridone
  • Pirfenidone also see 5-Methyl-1-Phenyl-2(1H)-Pyridinone
  • TORASEMIDETECHPIRFENIDONE
  • 5-Methyl-N-phenyl-2-1H-pyridone [Pirfenidone]
  • Pirfenidone(AMR-69)
  • Pirfenidone, 98%, an inhibitor for TGF-β production and TGF-β stimulated collagen
  • pirfenidone price
  • 5-Methyl-1-phenyl-2-pyridinone
  • Pirfenidone CRS
  • Pirfenidone&gt
  • Pirfenidone USP/EP/BP
  • 2-Amino-7-picoline
  • PirfenidoneQ: What is Pirfenidone Q: What is the CAS Number of Pirfenidone Q: What is the storage condition of Pirfenidone
  • PIRFINIDONE
  • Pirfenidone 5-methyl-1-phenylpyridin-2(1H)-one
  • Pirfenidone (S-7701)
  • Pirfenidone ( Anti- IPF )
  • Pirfenidone, orally active anti-inflammatory antifibrotic agent
  • Pirfenidone, 10 mM in DMSO
  • 53179-13-8
  • BioChemical
  • Cell Biology
  • Cell Signaling and Neuroscience
  • Immunomodulators and Antibiotics
  • Immune Cell Signaling and Blood
  • Immune System Regulation
  • Cytokine signaling
  • Inhibitors
  • Smad
  • TGF-beta
  • Aromatics Compounds
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • 53179-13-8